Skip to content

Trevi Therapeutics

US · TRVI #2810 by market cap Listed 2019
13.14 -0.04 -0.30%
Live - 5344 symbols - heartbeat 463s ago · 2026-10-08 04:33
Pre-market 13.39 +1.90%
After-hours 13.14 0.00%
Market cap
1.87B
P/B
5.82
EPS
-0.32
Reader sentiment Are you bullish or bearish on TRVI?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    BMO Capital Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $36
    Market Newswire · 2026/7/21
  • JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $28
    Market Newswire · 2026/8/14
  • Rating change
    Trevi Therapeutics (TRVI) Receives a New Rating From B. Riley Securities
    TipRanks · 2026/8/7
  • Rating change
    Clear Street Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $29
    Market Newswire · 2026/5/8
  • Rating change
    Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25
    Market Newswire · 2026/8/7
  • Rating change
    BMO Capital Initiates Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $36
    Market Newswire · 2026/7/21
  • Rating change
    H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $21
    Market Newswire · 2026/5/8
  • Trevi Therapeutics (TRVI) Receives a Buy From H.C. Wainwright
    TipRanks · 2026/9/22
  • Rating change
    Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23
    Market Newswire · 2026/7/17
  • Rating change
    A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $18 to $23
    Market Newswire · 2026/5/6
  • Rating change
    Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/8/7
  • Rating change
    Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
    Market Newswire · 2026/4/14
  • H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
    Market Newswire · 2026/9/22
  • Rating change
    Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $30
    Market Newswire · 2026/5/8
  • H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $24
    Market Newswire · 2026/7/20
  • Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23
    Market Newswire · 2026/8/10
  • Rating change
    Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $23
    Market Newswire · 2026/8/7
  • Rating change
    JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
    Market Newswire · 2026/5/7
  • Rating change
    Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
    Market Newswire · 2026/5/8
  • Rating change
    A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $40
    Market Newswire · 2026/8/8

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 04:33:25 · For reference only, not investment advice and not tailored to your situation.